Search
FibroGen Inc
FGENAdd to Watchlist
9.710USD
0.0000.00%
Close 07/01, 16:00（ET）Quotes delayed by 15 min
30.56MMarket Cap
0.18P/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
0.00%
5 Days
0.00%
1 Month
0.00%
6 Months
+10.59%
Year to Date
+10.59%
1 Year
+84.25%
Key Figures
--Open
0.000High
0.00Volume
0.18P/E TTM
--P/E Dynamic
--Dividend TTM
0.85%Turnover Ratio
9.710Prev. Close
0.000Low
0.00Turnover
LossP/E Static
-2.31P/B
0.00%Div Yield TTM
-26.04%ROA
21.93852wk High
1.36Volume Ratio
-47.58MNet Profit
4.04MShares
53.4422EPS TTM
0.84Beta
-42790.17%ROE
4.85052wk Low
5.76%Amplitude
94.62%Gross Margin
30.56MMarket Cap
1.57Reward/Risk
5.04%Risk Rate
TradingKey Stock Score of FibroGen Inc
Currency: USD Updated: 2026-01-07Key Insights
FibroGen Inc's fundamentals are relatively healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 103 out of 398 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 43.00.In the medium term, the stock price is expected to remain stable.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
FibroGen Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
FibroGen Inc Highlights
StrengthsRisks
FibroGen, Inc. is a biopharmaceutical company focused on the development of novel therapies at the frontiers of cancer biology and anemia. It is developing FG-3246, a potential first-in-class antibody-drug conjugate (ADC) targeting CD46, for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and potentially other cancers. This program also includes the development of FG-3180, an associated CD46-targeted positron emission tomography (PET) biomarker and imaging agent. It is also developing Roxadustat, an oral medication, first-in-class, oral small molecule hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), which is evaluated for the treatment of anemia in patients with chronic kidney disease (CKD), anemia associated with myelodysplastic syndromes and chemotherapy-induced anemia. Roxadustat is approved in China, Europe, Japan, and numerous other countries for the treatment of anemia of CKD in adult patients on dialysis (DD) and not on dialysis (NDD).
Growing
The company is in a growing phase, with the latest annual income totaling USD 29.62M.
Overvalued
The company’s latest PE is 0.18, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 1.14M shares, decreasing 33.14% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 184.24K shares of this stock.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
43.000
Target Price
+469.54%
Upside Space
FibroGen Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
FibroGen Inc Info
FibroGen, Inc. is a biopharmaceutical company focused on the development of novel therapies at the frontiers of cancer biology and anemia. It is developing FG-3246, a potential first-in-class antibody-drug conjugate (ADC) targeting CD46, for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and potentially other cancers. This program also includes the development of FG-3180, an associated CD46-targeted positron emission tomography (PET) biomarker and imaging agent. It is also developing Roxadustat, an oral medication, first-in-class, oral small molecule hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), which is evaluated for the treatment of anemia in patients with chronic kidney disease (CKD), anemia associated with myelodysplastic syndromes and chemotherapy-induced anemia. Roxadustat is approved in China, Europe, Japan, and numerous other countries for the treatment of anemia of CKD in adult patients on dialysis (DD) and not on dialysis (NDD).
Ticker SymbolFGEN
CompanyFibroGen Inc
CEOWettig (Thane)
Websitehttps://www.fibrogen.com/
Related Instruments
-0.64%
-0.05%
-0.23%
-1.64%
-2.41%
-2.95%
-0.22%
+1.75%
-0.29%
-0.79%
+0.26%
-2.00%
-2.10%
-2.41%
+1.68%
0.00%
+0.19%
-1.97%
+0.06%
-0.44%Popular Instruments
52283.200
+28.900 (+0.06%)
29667.500
-131.800 (-0.44%)
7476.400
+0.900 (+0.01%)
14791.000
-564.000 (-3.67%)
68549.000
-936.000 (-1.35%)
6290.000
+14.600 (+0.23%)
68.024
+0.056 (+0.08%)
294.380
+5.020 (+1.73%)
197.580
-2.510 (-1.25%)
4072.740
+41.970 (+1.04%)
FAQs
What is the current price of FibroGen Inc (FGEN)?
The current price of FibroGen Inc (FGEN) is 9.71.
What is the symbol of FibroGen Inc?
The ticker symbol of FibroGen Inc is FGEN.
What is the 52-week high of FibroGen Inc?
The 52-week high of FibroGen Inc is 21.94.
What is the 52-week low of FibroGen Inc?
The 52-week low of FibroGen Inc is 4.85.
What is the market capitalization of FibroGen Inc?
The market capitalization of FibroGen Inc is 30.56M.
Is FibroGen Inc (FGEN) currently rated as Buy, Hold, or Sell?
According to analysts, FibroGen Inc (FGEN) has an overall rating of Buy, with a price target of 43.00.
What is the Earnings Per Share (EPS TTM) of FibroGen Inc (FGEN)?
The Earnings Per Share (EPS TTM) of FibroGen Inc (FGEN) is 45.38.